Season 3 Ep. 10: Can Psychedelics Change the Pharmaceutical Industry?

Generation ETFs

コンテンツは Michael Brellisford and Horizons ETFs によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Michael Brellisford and Horizons ETFs またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

3y ago 27:45

MP3•エピソードのホーム

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on February 26, 2024 20:50 (2M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

After years of restrictions, Psychedelic compounds like psilocybin, ketamine and MDMA have been permitted to once again be studied and adapted into potential therapies for a variety of mental illnesses and could spark a revolution in the pharmaceutical industry. Join Mark Noble, Executive Vice President, ETF Strategy at Horizons ETFs as he speaks to psychedelics analyst Tania Gonsalves, Vice President, Equity Research at Canaccord Genuity about the emerging psychedelics industry and which companies are leading the way to unlocking potent new ways of treating mental illnesses.

42 つのエピソード